publication date: Oct. 12, 2018

Clinical Roundup New ASTRO/ASCO/AUA guideline for early-stage prostate cancer supports use of shortened courses of radiation therapy

Three medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy.

Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men. 

Developed by a panel of experts from the American Society for Radiation Oncology, American Society of Clinical Oncology and American Urological Association, the guideline recommends offering patients hypofractionated radiation therapy as an alternative to longer, conventional courses of radiation.

ASTRO, ASCO and AUA published the guideline in their respective journals, Practical Radiation Oncology, Journal of Clinical Oncology and The Journal of Urology.

“Conclusive evidence from several large, well-designed randomized trials now confirms that dose escalation can almost universally benefit men with early-stage prostate cancer who choose to manage their disease with external radiation,” said Howard Sandler, chair and professor of radiation oncology at Cedars-Sinai Medical Center and co-chair of the guideline panel. “Significant advances in treatment planning and delivery have enabled oncologists to deliver more powerful, life-saving doses of radiation in fewer visits and without compromising quality of life.” 

External beam radiation therapy … Continue reading New ASTRO/ASCO/AUA guideline for early-stage prostate cancer supports use of shortened courses of radiation therapy

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.